Nottingham-based cancer detection company Oncimmune Holdings has acquired a business in Germany for a total consideration of up to £4.11m.
Dortmund-based Protagen Diagnostics AG develops precision medicine and patient stratification tools for pharmaceutical multinationals in both immuno-oncology and autoimmune disease.
These tools support drug development, improve treatment strategies and patient management.
Oncimmune has said it intends to retain Protagen’s scientific team and the Dortmund laboratory to operate as its discovery research centre.
It added that Oncimmune’s Nottingham and Kansas facilities will continue to be responsible for the enlarged group’s product development, validation and production.
Chief executive Adam Hill said: “The acquisition of Protagen will accelerate Oncimmune’s product discovery process, will grow our library of known and novel immunogenic proteins, and will underpin the group’s ability to deliver value through the development of complementary diagnostics, a key component of our three-year forward strategy.
“Protagen’s biomarker discovery expertise and high throughput antigen screening technology are all highly synergistic to Oncimmune’s current capabilities. I look forward to working with our new colleagues to grow our company.”
By Jon Robinson
Source: Insider Media
The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.
Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.
Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.
